Dihexa
PNB-0408
- Molecular form
- Peptidomimetic
Peptidomimetic
Open the sources to check how the studies were done and what they can support.
An experimental angiotensin-derived peptidomimetic. A frequently cited 2014 paper on its proposed procognitive mechanism was retracted in 2025.
- Family
- Angiotensin-derived peptidomimetic
- Research target
- Proposed HGF/c-Met-related signaling
- Molecular form
- Peptidomimetic
What to know about the research
Retracted work must not be treated as affirmative evidence. Independent replication is needed before accepting mechanistic or cognitive claims.
Check the exact compound
Dihexa is not angiotensin IV itself. Identity does not resolve the reliability of a paper studying it.
What supports this entry?
1 of 3 summary statements linked to checked source passages.
These are selected references, not a complete review of the literature. Source checks were assisted by AI and have not received independent expert review.
Research stage, study quality and regulatory status answer different questions. A study card does not establish treatment benefit or approval.
Check the evidence limitationSource checked
Retracted work must not be treated as affirmative evidence. Independent replication is needed before accepting mechanistic or cognitive claims.
Publication title identifies a retraction notice for the cited 2014 mechanistic paper
- The notice is a reliability warning; it cannot support a positive mechanism or efficacy claim. Full notice rationale was not re-extracted in this migration.
No study details have been extracted for this exact entry yet. This does not mean that no studies exist. Open the references and check the exact material.
The remaining statements still need individual source mapping. Use the original references when checking a claim.
How we prepare and correct these entries